Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Yang Website

Li Yang, Ph.D.

Selected Publications

1)  Pang Y, Gara SK, Achyut BR, Li Z, Yan HH, Day CP, Weiss JM, Trinchieri G, Morris JC, Yang L.
TGF-ß Signaling in Myeloid Cells Is Required for Tumor Metastasis.
Cancer Discov. 3: 936-51, 2013.
2)  Achyut BR, Bader DA, Robles AI, Wangsa D, Harris CC, Ried T, Yang L.
Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-beta signaling.
PLoS Genet. 9: e1003251, 2013.
3)  Yan HH, Pickup M, Pang Y, Gorska AE, Li Z, Chytil A, Geng Y, Gray JW, Moses HL, Yang L.
Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung.
Cancer Res. 70: 6139, 2010.
4)  Li Z, Pang Y, Gara SK, Achyut BR, Heger C, Goldsmith PK, Lonning S, Yang L.
Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF-beta in breast cancer progression.
Int. J. Cancer. 131: 2584-95, 2012.
5)  Yang L, Pang Y, Moses HL.
TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.
Trends Immunol. 31: 220-7, 2010.
6)  Luger D, Yang YA, Raviv A, Weinberg D, Banerjee S, Lee MJ, Trepel J, Yang L, Wakefield LM.
Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects.
PLoS ONE. 8: e76115, 2013.
7)  Seton-Rogers S.
Microenvironment: Making connections.
Nat. Rev. Cancer. 13: 222-3, 2013.
8)  Faraji F, Pang Y, Walker RC, Nieves Borges R, Yang L, Hunter KW.
Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity.
PLoS Genet. 8: e1002926, 2012.
9)  Min Y, Ghose S, Boelte K, Li J, Yang L, Lin PC.
C/EBP-delta regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1alpha.
Oncogene. 30: 4901-9, 2011.
10)  Huang Y, Lin L, Shanker A, Malhotra A, Yang L, Dikov MM, Carbone DP.
Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth.
Cancer Res. 71: 6122-31, 2011.
11)  Boelte KC, Gordy LE, Joyce S, Thompson MA, Yang L, Lin PC.
Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1.
PLoS ONE. 6: e18534, 2011.
12)  Achyut BR, Yang L.
Transforming growth factor-beta in the gastrointestinal and hepatic tumor microenvironment.
Gastroenterology. 141: 1167-1178, 2011.
13)  Hembruff SL, Jokar I, Yang L, Cheng N.
Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms.
Neoplasia. 12: 425-33, 2010.
14)  Yang L.
TGFbeta and cancer metastasis: an inflammation link.
Cancer Metastasis Rev. 29: 263-71, 2010.
15)  Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Moses HL.
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.
Cancer Cell. 13: 23-35, 2008.
16)  Yang L, Moses HL.
Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer?.
Cancer Res. 68: 9107-11, 2008.
17)  Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, Forrester E, Yang L, Wagner KU, Moses HL.
Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
Cancer Res. 68: 1809-19, 2008.
18)  Yang L, Amann JM, Kikuchi T, Porta R, Guix M, Gonzalez A, Park KH, Billheimer D, Arteaga CL, Tai HH, DuBois R, Carbone DP, Johnson DH.
Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer.
Cancer Res. 67: 5587-93, 2007.
19)  Yang L, Huang Y, Porta R, Yanagisawa K, Gonzalez A, Segi E, Johnson DH, Narumiya S, Carbone DP.
Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism.
Cancer Res. 66: 9665-72, 2006.
20)  Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC.
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.
Cancer Cell. 6: 409-21, 2004.
21)  Yang L, Carbone DP.
Tumor-host immune interactions and dendritic cell dysfunction.
Adv. Cancer Res. 92: 13-27, 2004.
22)  Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD, Shyr Y, Boothby M, Joyce S, Carbone DP, Breyer RM.
Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor.
J. Clin. Invest. 111: 727-35, 2003.
Click Here to View Collapsed Bibliography.

This page was last updated on 6/17/2014.